Statistical Considerations for Clinical Trials During COVID-19: Background, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: An Adaptive Hybrid Design for Clinical Development in Rare Diseases, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials in Patients with COVID-19 High Risks, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Accurate COVID-19 Testing in Clinical Trials, Stephan Ogenstad, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Blinded Data Review for Adaptive Estimands (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: A Two-Stage Adaptive Design for Clinical Trials with Chronic Conditions, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Minimization Randomization and Mitigations, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Impacts on Permuted Block Randomization and Mitigations, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Integrated Analysis of Efficacy (IAE) with Adaptive Estimands, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Interim Analysis with Adaptive Estimands Based, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part I), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part III), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Natural History Controls for Survival Analysis (Part II), Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Phase 1 Cancer Trials, Michael T. Tirgan, Qing Liu, Karl E. Peace
Karl E. Peace

Statistical Considerations for Clinical Trials During COVID-19: Steps for Mitigation, Qing Liu, Karl E. Peace
Karl E. Peace